Search clinical trials for: NNZ-2566

Total 208 results

GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
Applied Spine Technologies

Terminated

Dynamic Stabilization for Lumbar Spinal Stenosis With Stabilimax NZ® Dynamic Spine Stabilization System

Lumbar Spinal Stenosis

United States
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Cystic Fibrosis

United States
VA Office of Research and Development

Enrolling by invitation

Notched Noise Therapy for Suppression of Tinnitus

Tinnitus | Notched Noise Therapy

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

Chronic Hepatitis B

Singapore
University of Nevada, Las Vegas

Recruiting

Ostomy Primary Closure With 0.1% Betaine/0.1% Polyhexanide Wound Irrigation Compared to Pursestring Closure

Colorectal Disorders | Surgical Site Infection | Wound Surgical

United States
Pennington Biomedical Research Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Low Oxygen Exposure and Weight Status (LOWS)

Obesity

United States
University Hospital of North Norway
University of Bergen; The Research Council of Norway; Haukeland University Hospital and other collaborators

Enrolling by invitation

Measures for Bioaerosol Reduction in the Salmon Industry (SHInE)

Hypersensitivity | Asthma, Occupational

Norway
University of Auckland, New Zealand
Waitemata District Health Board; University of Alaska Anchorage

Completed

Feasibility of a Smart-phone Based Support System for Hazardous Drinkers (NZStepAway)

Alcohol Consumption

New Zealand
Inozyme Pharma

Recruiting

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

United States
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc; MEDPHASE CLINICAL RESEARCH CONSULTANT... and other collaborators

Active, not recruiting

A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) (CKD)

Anemia | Chronic Kidney Disease Requiring Chronic Dialysis

Vietnam
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Vaxart

Completed

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)

Norovirus Infections

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Minervax ApS

Completed

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age. (MVX13211)

Infection by Streptococcus Group B

United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Prevention of the Meningococcal Disease

Germany
Vaxart

Completed

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Norovirus Gastroenteritis

United States
Pacira Pharmaceuticals, Inc

Completed

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

Postoperative Pain

United States
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
Vaxart

Completed

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)

Norovirus Infections

United States
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Terminated

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms
University Hospitals Bristol and Weston NHS Foundation...
Public Health England; University of Bristol; Novartis Vaccines; North Bristol...

Completed

Regulation of Mucosal Immune Response to Systemic MenB Vaccine

Meningococcal Infections

United Kingdom
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Diabetes Mellitus, Type 2 | Diabetes

United States
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
Exeltis France
Insud Pharma

Completed

Benznidazole Absorption, Metabolism and Excretion Study

Healthy Male Subjects

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novartis Vaccines
Novartis

Completed

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

Meningococcal Disease | Meningococcal Meningitis

Italy
Cocrystal Pharma, Inc.

Completed

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Chronic Hepatitis C

United States
University of Aberdeen

Recruiting

Scot Sweet Study (Interaction of a Non-nutritive Sweetener With a High-fibre Weight Loss Diet) (SSS)

Appetitive Behavior

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
Romark Laboratories L.C.

Not yet recruiting

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

COVID-19
Novo Nordisk A/S

Completed

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Diabetes Mellitus, Type 2 | Diabetes

United States
University of California, San Francisco

Completed

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery (Exparel)

Pain, Postoperative | Bariatric Surgery Candidate

United States
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Wake Forest University Health Sciences

Completed

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

Postoperative Pain

United States
Drugs for Neglected Diseases
LAT Research

Completed

Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease (Pop PK Chagas)

Chagas' Disease

Argentina
Romark Laboratories L.C.

Recruiting

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Rhinovirus | Enterovirus

United States
Romark Laboratories L.C.

Completed

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

COVID-19

United States

3

Subscribe